drugset / Trial / NCT06110676
A Study to Evaluate the Efficacy and Safety of LZM012
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
Timeline
- Start
- 2023-08-21
- Primary completion
- 2025-04
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LZM012 | Monoclonal antibody | 320 mg | — |
| Comparator | Secukinumab | Monoclonal antibody | 300 mg | — |